Valuation: Arcus Biosciences, Inc.

Market Cap 381.47Cr 333.48Cr 306.47Cr 285.66Cr 541.82Cr 36TCr 550.04Cr 3.68TCr 1.43TCr 18TCr 1.43TCr 1.4TCr 62TCr P/E 2026 *
-8.25x
P/E 2027 * -8.99x
Enterprise Value 319.34Cr 279.16Cr 256.55Cr 239.14Cr 453.57Cr 30TCr 460.45Cr 3.08TCr 1.2TCr 15TCr 1.2TCr 1.17TCr 52TCr EV / Sales 2026 *
37.5x
EV / Sales 2027 * 38.2x
Free-Float
70.85%
Yield 2026 *
-
Yield 2027 * -
1 day+4.88%
1 week-2.16%
Current month-1.62%
1 month+27.12%
3 months+32.10%
6 months+30.23%
Current year+27.28%
1 week 28.78
Extreme 28.775
31.74
1 month 21.84
Extreme 21.84
31.74
Current year 18.52
Extreme 18.515
31.74
1 year 8.03
Extreme 8.03
31.74
3 years 6.5
Extreme 6.5
31.74
5 years 6.5
Extreme 6.5
49.1
10 years 6.3
Extreme 6.3
49.1
Manager TitleAgeSince
President 68 01/05/2015
Chief Executive Officer 67 01/05/2015
Director of Finance/CFO 53 01/08/2020
Director TitleAgeSince
Chairman 67 01/12/2017
Director/Board Member 65 18/09/2017
Director/Board Member 71 01/05/2015
Date Insider Type Main position Quantity % Market Cap.
24/06Sell

Founder

-6,431 0.0051%
11/06Free

Director

22,600 0.0180%
11/06Free

Director

22,600 0.0180%
Change 5-day change 1-year change 3-year change Capi.($)
+4.88%-2.16%+258.09%+48.39% 381.47Cr
+1.70%+7.41%+3.12%+8.46% 4.99TCr
+0.92%+3.93%+399.71%+605.33% 4.02TCr
+1.89%+8.32%+26.06%-6.35% 3.46TCr
+2.38%+6.35%+21.25%+64.58% 3.31TCr
+3.96%+10.67%+11.89%+38.86% 2.75TCr
+2.51%+5.27% - - 1.7TCr
+2.58%+5.79%+73.44%+133.27% 1.59TCr
+0.32%+0.58%+13.67%+19.09% 1.39TCr
+3.30%+0.76%+90.23%+99.12% 1.35TCr
Average +2.44%+5.27%+99.72%+112.31% 2.49TCr
Weighted average by Cap. +2.11%+6.44%+93.49%+136.28%

Financials

2026 *2027 *
Net sales 8.51Cr 7.44Cr 6.83Cr 6.37Cr 12Cr 809.9Cr 12Cr 82Cr 32Cr 398.11Cr 32Cr 31Cr 1.37TCr 9.31Cr 8.14Cr 7.48Cr 6.97Cr 13Cr 886.04Cr 13Cr 90Cr 35Cr 435.53Cr 35Cr 34Cr 1.5TCr
Net income -46Cr -40Cr -37Cr -34Cr -65Cr -4.35TCr -66Cr -440.17Cr -171.11Cr -2.14TCr -171.31Cr -167.63Cr -7.36TCr -43Cr -38Cr -35Cr -32Cr -61Cr -4.1TCr -62Cr -415.24Cr -161.42Cr -2.01TCr -161.6Cr -158.13Cr -6.94TCr
Net Debt -62Cr -54Cr -50Cr -47Cr -88Cr -5.92TCr -90Cr -599.26Cr -232.96Cr -2.91TCr -233.22Cr -228.22Cr -10TCr -26Cr -23Cr -21Cr -19Cr -37Cr -2.47TCr -37Cr -250.14Cr -97Cr -1.21TCr -97Cr -95Cr -4.18TCr
Logo Arcus Biosciences, Inc.
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
Employees
601
Date Price Change Volume
02/26/02 $30.33 +4.88% 13,25,784
01/26/01 $28.92 -6.20% 16,64,831
30/26/30 $30.83 -0.80% 13,44,884
29/26/29 $31.08 +0.26% 15,65,332
26/26/26 $31.00 +2.48% 43,52,591
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
30.33USD
Average target price
35.75USD
Spread / Average Target
+17.87%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RCUS Stock